Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the potential effect of the Voluntary Scheme for Branded Medicines Pricing Access on (a) global R&D investment decisions and (b) access to medical innovation.

The Government is working to better understand the impacts the operation of the current Voluntary Scheme on investments in the UK and access to medicines. We are therefore in direct conversations with companies to understand these impacts. The Department for Business, Energy and Industrial Strategy is in close discussions with the Department of Health and Social Care, the Department responsible for the Voluntary Scheme, about the business environment for life sciences and its impact on investment and patient access.